Published in World J Gastroenterol on April 07, 2016
Update on occult hepatitis B virus infection. World J Gastroenterol (2016) 0.75
Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia. PLoS One (2017) 0.75
Occult Hepatitis Infection in Transfusion Medicine: Screening Policy and Assessment of Current Use of Anti-HBc Testing. Transfus Med Hemother (2017) 0.75
Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell (1986) 42.45
Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. Cell (1982) 16.71
Hepatitis B virus biology. Microbiol Mol Biol Rev (2000) 7.58
Vaccine-induced escape mutant of hepatitis B virus. Lancet (1990) 5.31
The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci U S A (1991) 4.37
Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci U S A (1989) 3.67
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet (1999) 3.17
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med (1999) 3.08
Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology (2009) 3.05
Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy. Hepatology (2011) 2.93
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology (2004) 2.87
Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet (1995) 2.82
Virus glycosylation: role in virulence and immune interactions. Trends Microbiol (2007) 2.64
Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology (2005) 2.49
Control of cccDNA function in hepatitis B virus infection. J Hepatol (2009) 2.41
High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. J Hepatol (2012) 2.41
Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol (1994) 2.41
Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med (1978) 2.30
Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication. J Virol (1989) 2.21
Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol (1993) 2.16
Assembly of hepadnaviral virions and subviral particles. Curr Top Microbiol Immunol (1991) 2.02
Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology (1998) 2.01
High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol (2001) 1.94
Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J Exp Med (1987) 1.93
Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS (2002) 1.92
Occult hepatitis B virus infection: implications in transfusion. Vox Sang (2004) 1.85
Occult hepatitis B virus infection and its clinical implications. J Viral Hepat (2002) 1.82
Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology (2006) 1.81
Hepatitis B virus genetic variability and evolution. Virus Res (2007) 1.80
Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology (2011) 1.74
A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci U S A (1986) 1.74
Transfusion-transmitted hepatitis B virus infection. J Hepatol (2009) 1.70
Occult hepatitis B virus infection: a covert operation. J Viral Hepat (2009) 1.69
Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis (1998) 1.69
International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang (2011) 1.69
Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis (2007) 1.69
Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol (2002) 1.68
Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology (2001) 1.61
N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape. J Hepatol (2013) 1.57
Multiple liver-specific factors bind to the hepatitis B virus core/pregenomic promoter: trans-activation and repression by CCAAT/enhancer binding protein. Proc Natl Acad Sci U S A (1990) 1.54
Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology (2002) 1.53
Functional analysis of complex hepatitis B virus variants associated with development of liver cirrhosis. Gastroenterology (2006) 1.46
Clinical impact of occult HBV infections. J Clin Virol (2005) 1.46
Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol (2000) 1.44
The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology (2008) 1.42
The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology (2008) 1.41
Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology (2004) 1.40
Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol (1999) 1.40
Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect (2009) 1.39
Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants. J Virol (2006) 1.39
Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology (2000) 1.38
Identification of three essential regions of hepatitis B virus X protein for trans-activation function. Oncogene (1992) 1.38
Occult HBV infection. Semin Immunopathol (2012) 1.37
Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol (1992) 1.37
The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol (2000) 1.36
Prevalence of antibodies to hepatitis B core antigen and occult hepatitis B virus infections in Korean blood donors. Transfusion (2011) 1.35
Serum Levels of IL-10 and IL-17A in Occult HBV-Infected South-East Iranian Patients. Hepat Mon (2010) 1.34
Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion (2007) 1.32
Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol (2008) 1.31
Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology (2007) 1.31
Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion (2008) 1.31
Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology (2011) 1.30
Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology (2004) 1.30
Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol (2012) 1.29
Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Semin Liver Dis (2013) 1.28
Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. Immunol Rev (2000) 1.28
Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol (2014) 1.27
Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology (2000) 1.26
Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles. J Virol (1996) 1.25
Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology (2010) 1.23
A new enhancer element, ENII, identified in the X gene of hepatitis B virus. J Virol (1990) 1.23
Selected mutations of the duck hepatitis B virus P gene RNase H domain affect both RNA packaging and priming of minus-strand DNA synthesis. J Virol (1994) 1.22
Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J Hepatol (2008) 1.22
Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood (2003) 1.19
Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. Hepatology (2000) 1.16
Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology (1999) 1.15
Effect of variation in the common "a" determinant on the antigenicity of hepatitis B surface antigen. J Med Virol (2000) 1.13
A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology (1997) 1.13
The amino Acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. J Clin Microbiol (2007) 1.12
Naturally occurring mutations in large surface genes related to occult infection of hepatitis B virus genotype C. PLoS One (2013) 1.11
Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. Gut (2010) 1.11
Hepatitis B virus DNA in peripheral-blood mononuclear cells in chronic hepatitis B after HBsAg clearance. Hepatology (1992) 1.10
Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterol (2007) 1.09
Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion. J Virol (2009) 1.08
Hepatitis C virus is frequently coinfected with serum marker-negative hepatitis B virus: probable replication promotion of the former by the latter as demonstrated by in vitro cotransfection. J Med Virol (1997) 1.08
Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci (2010) 1.06
Subgenotypes of hepatitis B virus genotype D (D1, D2, D3 and D5) in India: differential pattern of mutations, liver injury and occult HBV infection. J Viral Hepat (2009) 1.06
The small envelope protein is required for secretion of a naturally occurring hepatitis B virus mutant with pre-S1 deleted. J Virol (1997) 1.05
Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis (2008) 1.04
Occult hepatitis B infection: an evolutionary scenario. Virol J (2008) 1.03
Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol (2010) 1.02
Deficiency in virion secretion and decreased stability of the hepatitis B virus immune escape mutant G145R. Hepatology (2003) 1.02
Molecular characterization and functional analysis of occult hepatitis B virus infection in Chinese patients infected with genotype C. J Med Virol (2009) 1.01
Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol (2003) 1.01
Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. J Med Virol (2006) 1.01
Regulation of hepatitis B virus replication by epigenetic mechanisms and microRNAs. Front Genet (2013) 0.99
Regulation of transcription from the hepatitis B virus major surface antigen promoter by the Sp1 transcription factor. J Virol (1992) 0.99